FDA Drug Reviews Pass Muster As User Fee Deadline Looms
GAO, in a report requested by Sens. Richard Burr, R-N.C., and Tom Coburn, R-Okla., found that the FDA met performance goals, outlined in past Prescription Drug User Fee Agreements, on review times for new drug and biologic applications.
The report could...
To view the full article, register now.